T-105 Injectable Drug Recalled for Manufacturing Practice Deviations
Olympia Compounding Pharmacy is recalling T-105 injectables nationwide due to manufacturing process deviations. Environmental and personnel monitoring failures prior to October 2021 were not properly investigated.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable compounded drug based on manufacturing control deviations. No illnesses or injuries are reported in the source, but the manufacturing process failure in environmental and personnel monitoring of an injectable product represents a risk-of-harm situation consistent with High severity.
Plain-English summary
Olympia Compounding Pharmacy is recalling T-105 (Papaverine 30mg/mL, Phentolamine 1mg/ml, and PGE 10mcg/ml) in 10ml, 5ml, and 2.5ml vials. Approximately 6,916 vials have been distributed nationwide in the United States. The product is a prescription-only injectable medication.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations. Prior to October 1, 2021, excursions in environmental and personnel monitoring that exceeded allowable action limits were not being properly investigated.
Patients and healthcare providers who have received this product should consult with their healthcare provider regarding continued use. Patients should not discontinue use without medical guidance. Specific affected lot numbers and beyond-use dates are available from the FDA or the manufacturer.
The recalled product
- Product
- T-105, Papaverine 30mg/mL . Phentolamine 1mg/ml . PGE 10mcg/ml, , Packaged as a) 10 ml Multi-Dose vial, NDC 73198-0005-10; b) 5 ml Multi-Dose vial, NDC 73198-0005-05; c) 2.5 ml Multi-Dose vial, NDC 73198-0005-03; Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlan
- Category
- Drug — Compounded Injectable
- Affected units
- 6,916
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lots: a) D41412 BUD: 4/22/2022
- E41F10 BUD: 5/10/2022
- E41G10 BUD: 5/10/2022
- F24D21 BUD: 6/21/2022
- b) D41512 BUD: 4/12/2022
- c) F42B21 BUD: 6/21/2022
- H42B03 BUD: 8/3/2022
- H42C03 BUD: 8/3/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 34 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 34 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighLidocaine 2% injectable solution recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29